Takeda unit urges Fed Circ to revive antibody patent

Baxalta, a subsidiary of Japan-headquartered pharmaceutical company Takeda, has asked the US Court of Appeals for the Federal Circuit to overturn a decision that invalidated its antibody patent.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Regulation & Industry

G 1/25: EPO settles controversial patent description question

4 September 2026 Clarity from the Enlarged Board of Appeal for when patent descriptions must be amended to reflect changes to the claims has finally arrived. LSIPR outlines G 1/25, the debate that led to the referral and the EPC provisions at the heart of the ruling.

Biotech

10x Genomics wins latest round in Parse patent dispute

3 September 2026 Turnaround for 10x after Federal Circuit setback as Delaware jury finds Qiagen-owned Parse infringed three patents covering single-cell sequencing technology.

MedTech

Sun Pharma import ban back in force after Squires intervention

3 September 2026 A decision at the USPTO has cleared the way for renewed enforcement in the drugmaker’s dispute over light-based dermatology tech.